AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25327872
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of double‐balloon catheter and oral misoprostol
Trial: 21067880
Drug: Iodine concentration
RxNorm normalized name: iodine Topical Solution [QuarterMate Concentrate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine concentration of 370 mg I/mL (Group B)
Trial: 21067880
Drug: Iodine concentration
RxNorm normalized name: iodine Topical Solution [QuarterMate Concentrate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine concentration of 300 mg I/mL (Group A)
Trial: 19308807
Drug: Add-on intraprostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on intraprostatic BoNT‐A injection (200-600 U of Botox)
Trial: 15452006
Drug: Ads incorporating
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ads incorporating a prescription drug benefit box
Trial: 15452006
Drug: Ads without
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ads without a prescription drug benefit box
Trial: 15452006
Drug: General perception
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: General perception of benefit data in drug ads
Trial: 30309327
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (SMI) 0.6 mL/kg administered intravenously from the time of anesthesia induction to the beginning of CPB.
Trial: 21601343
Drug: CRQ-SAS (self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRQ-SAS (self-administered version)
Trial: 21601343
Drug: CRQ-IA (interviewer-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRQ-IA (interviewer-administered version)
Trial: 18468272
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (BTX‐A)
Trial: 16820551
Drug: Acetaminophen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4 g daily)
Trial: 1803767
Drug: Live recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live recombinant influenza vaccine
Trial: 24855368
Drug: SIMVA 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIMVA 10, 20, or 40 mg
Trial: 24855368
Drug: ERN/LRPT 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT 1 g/20 mg + SIMVA (10, 20, or 40 mg)
Trial: 18831744
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg (two 40 mg injections at baseline followed by one 40 mg injection every other week from Week 1 to Week 15)
Trial: 12944570
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg of everolimus per day
Trial: 12944570
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of everolimus per day
Trial: 12944570
Drug: Azathioprine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (1.0 to 3.0 mg per kg per day)
Trial: 10944065
Drug: Endomysium antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endomysium antibodies
Trial: 10944065
Drug: IgA-gluten antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA-gluten antibodies
Trial: 10944065
Drug: IgG-gluten antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG-gluten antibodies
Trial: 8937483
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (CDDP 16 mg/m2 for 5 days with 5-FU 700 mg/m2/day for 5 days)
Trial: 8937483
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (CDDP 80 mg on day 1 with 5-FU 700 mg/m2/day for 5 days)
Trial: 8937483
Drug: UFT adjuvant
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT adjuvant chemotherapy (600 mg/day from day 1 to day 14) with CBDCA (350 mg/m2 on day 7)
Trial: 1587073
Drug: Fenfluramine plus
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine plus phentermine (60 mg fenfluramine plus 30 mg phentermine)
Trial: 1587073
Drug: Fenfluramine plus
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine plus phentermine (continued therapy)
Trial: 1587073
Drug: Targeted intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted intermittent therapy
Trial: 2858708
Drug: Thymopentin (TP-5)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (TP-5) 50 mg 3 times a week for 3 consecutive weeks
Trial: 29492613
Drug: 0.56 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.56 g/kg alcohol in a vodka and tonic-mixed drink
Trial: 29492613
Drug: Placebo (tonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tonic with 4 ml of vodka sprayed on top)
Trial: 27869096
Drug: 21-Gy involved-field
RxNorm normalized name: FIELD MUSHROOM
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-Gy involved-field radiation therapy (IFRT)
Trial: 25086593
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with advice on increasing physical activity and a sham treatment
Trial: 20637390
Drug: Phloroglucinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol (200 mg) with piroxicam (20 mg)
Trial: 20637390
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with piroxicam (20 mg)
Trial: 16834644
Drug: Propiverine 15
RxNorm normalized name: propiverine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 15 mg three times daily
Trial: 16834644
Drug: Propiverine 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine 45 mg
Trial: 16834644
Drug: Oxybutynin 15
RxNorm normalized name: oxyBUTYnin 15 mg/24 hr oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 15 mg
Trial: 12907830
Drug: Ferric hydroxide-polymaltose
RxNorm normalized name: ferric hydroxide
DrugBank: Ferric hydroxide (DB13423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferric hydroxide-polymaltose complex (Ferrum, Vifor, Switzerland) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Trial: 12907830
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate complex (FerroSanol, Schwarz, Germany) 6 mg/d for 3 months, then 3 mg/kg for 3 months
Trial: 11003764
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (n = 167)
Trial: 8975951
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 300 mg orally twice a day
Trial: 8975951
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg orally BID
Trial: 1477017
Drug: Labetalol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (up to 600 mg daily)
Trial: 31324181
Drug: Cornelian cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornelian cherry extract (320 mg/day of anthocyanins) for 12 weeks
Trial: 22980596
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy (EIS) using either ethanolamine oleate 5% or N‐butyl cyanoacrylate
Trial: 20029189
Drug: Nicergoline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (15 mg t.i.d.)
Trial: 20029189
Drug: Nicergoline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (15 mg t.i.d.) in patients with bilateral basal ganglia involvement
Trial: 20029189
Drug: Nicergoline (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (15 mg t.i.d.) in patients with no or unilateral basal ganglia involvement
Trial: 9396885
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (dinoprostone) 3 mg
Trial: 8186906
Drug: Almitrine bimesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bimesylate (AB) 50-100 mg/day
Trial: 3073869
Drug: 5 MU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU/m2 human lymphoblastoid interferon (Wellferon), three times weekly for 6 months
Trial: 29065815
Drug: Bio-oxidative ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-oxidative ozone therapy (OG, n = 20)
Trial: 21830011
Drug: Misoprostol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (400 μg vaginal)
Trial: 11981594
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day sertraline
Trial: 11981594
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day sertraline plus 30 mg/day mianserin
Trial: 11981594
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day sertraline
Trial: 7876651
Drug: Two injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections on day 0
Trial: 7876651
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection on day 0 and 14
Trial: 7876651
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection on day 0 and 30
Trial: 7876651
Drug: One injection
RxNorm normalized name: naloxone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One injection on day 0 and 180
Trial: 7876651
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose on day 380
Trial: 2197845
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of 400 micrograms octreotide per day
Trial: 31129874
Drug: Preventive and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive and interceptive orthodontic treatment needs (P&I Tx need) as assessed by the Index for Preventive and Interceptive Orthodontic Needs (IPION)
Trial: 31129874
Drug: IPION scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPION scores in the definite treatment need group
Trial: 27554812
Drug: Daily pasteurized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pasteurized raw whole egg powder
Trial: 25772960
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (divided doses)
Trial: 25772960
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily intake of Low Molecular Weight (LMW) iron dextran
Trial: 24012983
Drug: Aspiration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration therapy plus lifestyle therapy (n=11)
Trial: 24012983
Drug: Lifestyle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle therapy only (n=7)
Trial: 24012983
Drug: Aspiration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration therapy (n=10 who completed additional year)
Trial: 15101486
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 10 milliliters of lidocaine around the drain tube during removal
Trial: 7512583
Drug: Topical retinoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoid AGN 190168
Trial: 31520370
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (pantoprazole 80 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and metronidazole 1000 mg daily in divided doses for 14 days)
Trial: 31520370
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (pantoprazole 80 mg, amoxicillin 2000 mg, and clarithromycin 1000 mg daily in divided doses for 14 days)
Trial: 29114833
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg) and acetaminophen (1000 mg)
Trial: 29114833
Drug: Oxycodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (5 mg) and acetaminophen (325 mg)
Trial: 29114833
Drug: Hydrocodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone (5 mg) and acetaminophen (300 mg)
Trial: 29114833
Drug: Codeine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (30 mg) and acetaminophen (300 mg)
Trial: 29114833
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of oxycodone and acetaminophen vs hydrocodone and acetaminophen
Trial: 15507095
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SIT) with tree pollen (birch)
Trial: 9513073
Drug: Zolpidem, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem, 10 mg, administered continuously
Trial: 9513073
Drug: Zolpidem, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem, 10 mg, administered intermittently (five nights zolpidem, two consecutive nights placebo per week)
Trial: 8062354
Drug: 60-90 mg
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60-90 mg amitriptylinoxide (AO)
Trial: 8062354
Drug: 50-75 mg
RxNorm normalized name: hydrochlorothiazide 50 MG / triamterene 75 MG [Maxzide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-75 mg amitriptyline (AM)
Trial: 3123092
Drug: O-desmethyl encainide
RxNorm normalized name: 5-o-desmethyl omeprazole
DrugBank: YA-101 (DB18121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-desmethyl encainide (ODE) infusion
Trial: 3123092
Drug: 3-methoxy-O-desmethyl encainide
RxNorm normalized name: 5-o-desmethyl omeprazole
DrugBank: YA-101 (DB18121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-methoxy-O-desmethyl encainide (3MODE) infusion
Trial: 3123092
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of encainide therapy
Trial: 3123092
Drug: ODE infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODE infusion
Trial: 3123092
Drug: 3MODE infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3MODE infusion
Trial: 31976311
Drug: FMT-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMT-L
Trial: 23042922
Drug: Single-dose gadobenate
RxNorm normalized name: gadobenate
DrugBank: Gadobenic acid (DB00743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose gadobenate dimeglumine
Trial: 23042922
Drug: Double-dose gadopentetate
RxNorm normalized name: gadopentetate
DrugBank: Gadopentetic acid (DB00789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose gadopentetate dimeglumine
Trial: 19815913
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg once daily for 14 days)
Trial: 19815913
Drug: Comparator (doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (doxycycline 100 mg twice daily + metronidazole 400 mg three times daily for 14 days + single 500 mg ciprofloxacin dose)
Trial: 12602538
Drug: Atorvastatin (T2DA)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (T2DA)
Trial: 8813038
Drug: Zidovudine alone
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine alone (600 mg)
Trial: 8813038
Drug: Zidovudine plus
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine plus didanosine (600 mg + 400 mg)
Trial: 8813038
Drug: Zidovudine plus
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine plus zalcitabine (600 mg + 2.25 mg)
Trial: 8813038
Drug: Didanosine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine alone (400 mg)
Trial: 1363986
Drug: Sulfasalazine, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine, daily dosage of 2 g
Trial: 3591726
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A capsule (200,000 IU)
Trial: 25850817
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (where intravascular injections did not occur)
Trial: 19542686
Drug: Regular intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intake of multivitamin supplement 5 years before diagnosis
Trial: 16410483
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (dalteparin; 100 IU/kg BID)
Trial: 9440362
Drug: Maximal onset
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal onset principle (e.g., MAR-KET)
Trial: 9440362
Drug: Stress principle
RxNorm normalized name: Muguettine principle
DrugBank: Hydroxycitronellal (DB14187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress principle (e.g., MARK-ET)
Trial: 3065687
Drug: IFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha‐2b at 1 x 10(6) U twice a week (maintenance therapy)
Trial: 3065687
Drug: IFN alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha‐2b at 2 x 10(6) U once weekly (maintenance therapy)
Trial: 31887617
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice and tablets
Trial: 31887617
Drug: Placebo-matching juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching juice and tablets
Trial: 21198431
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) + zidovudine (ZDV) + lamivudine (3TC) triple therapy
Trial: 12763982
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (group A)
Trial: 11785865
Drug: Medication trolley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication trolley at the patient's bedside
Trial: 3798631
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg X 3)
Trial: 3798631
Drug: Estramustine (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estramustine (280 mg X 2)
Trial: 19522391
Drug: Liqi decoction
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liqi decoction (oral for 2 to 3 days)
Trial: 2824707
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (1,200 mg/m2), doxorubicin (70 mg/m2), and vincristine (1 mg/m2) (HDCAV)
Trial: 2824707
Drug: Conventional-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose cyclophosphamide (1,000 mg/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2) (CDCAV)
Trial: 10155051
Drug: Aerosolized albuterol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized albuterol and cromolyn sulfate
Trial: 10155051
Drug: Home aerosol
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home aerosol treatments after intramuscular injection of dexamethasone
Trial: 6369456
Drug: Chlorpropamide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpropamide (single dose)
Trial: 22075273
Drug: Walnut-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-enriched diet (48 g/d for 4 days)
Trial: 19412190
Drug: Topical nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin formulation
Trial: 19412190
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment options
Trial: 15197669
Drug: Arndt bronchial
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arndt bronchial blocker (BB)
Trial: 11967497
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (E(2)/NETA)
Trial: 9717036
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sublingual 17 beta-oestradiol
Trial: 9717036
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg buccal nitroglycerine
Trial: 3400639
Drug: AST-120 (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (3.2 to 7.2 g/d) administered for 2.4 to 30.1 months (mean 13.2 +/- 7.4 months)